EnsoData has closed a $20 million series A extension led by Inspire Medical Systems Inc, with participation from existing investors including Zetta Venture Partners, Venture Investors, Supermoon Capital, Colle Capital, HealthX Ventures, M25 Ventures, board members Justin Mortara, Fred Robertson, MD, and other investors.
The company is also expanding its leadership team with the appointment of Justin Mortara, PhD, as president. Coupled with funding and new partnerships, EnsoData’s latest additions to its senior leadership team will help the company quickly scale to accelerate the adoption of AI technology across healthcare.
Through partnerships with more than 100 provider organizations’ 500+ clinics across the United States, over 500,000 patients have already benefited from EnsoData’s technology, and the company is helping 32,000+ new patients each month.
In the past year, EnsoData received its second FDA clearance, doubled its team in size, expanded partnerships with providers worldwide, and extended further support for virtual and at-home diagnostics.
With this new funding, EnsoData will rapidly scale multinational expansion and commercial distribution partnerships, continue building out its team, and expand its product offerings to address new customer use cases and features to enable more accurate, affordable, and accessible care globally.
As president, Mortara will support EnsoData’s vision by preparing the company for scale in its next stage of growth—expanding EnsoData’s team, advancing its commercial strategy, and identifying new strategic opportunities. He brings 20 years of experience as an executive leader, innovator, and investor across digital health and life sciences. Previously he spent over 20 years at Mortara Instrument, a provider of diagnostics for cardiovascular disease, where as CEO he led the company to over 10x growth and market leadership, culminating in its acquisition in 2017 by Hillrom (Baxter) for $330 million. Prior to joining in this role, Justin was EnsoData’s executive chairman and also managed a portfolio of early-stage healthcare investments spanning devices, tech-enabled services, and life sciences.
EnsoData’s technology is trained on a sleep database that includes more than 1,000,000 patient sleep studies and over 7,000,000 hours of resulting health waveform data.
Chris Fernandez, CEO and co-founder of EnsoData, says in a release, “EnsoData and its impactful technology represent an opportunity to improve the experience of treatment for patients and providers and accelerate big-picture shifts by opening greater access to diagnosis. Our proven, clinically validated technology has generated real demand and traction and as we continue to scale our team and growth. With this confluence of new funding, new partnerships, and the addition of industry veterans like Justin to our team, we’re even better positioned today to continue our upward trajectory and to successfully navigate the evolving state of healthcare.”
Mortara says in a release, “I’ve had the great pleasure to advise Chris and the EnsoData team for the last two years. During that time I have come to appreciate their culture, passion, and tremendous innovations in sleep. Drawing on my experience in cardiology, I see enormous potential for further growth and I am excited to start this next chapter as president.”